Loading...
XSTO
ALZ
Market cap19mUSD
Jun 13, Last price  
1.78SEK
1D
4.71%
1Q
-32.06%
Jan 2017
-89.12%
IPO
-85.23%
Name

Alzinova AB

Chart & Performance

D1W1MN
P/E
—
P/S
6,189.89
EPS
—
Div Yield, %
—
Shrs. gr., 5y
51.58%
Rev. gr., 5y
-66.21%
Revenues
30k
-88.89%
2,189,961839,373954,334998,3875,252,9515,790,9629,360,0576,808,83714,898,03417,321,73816,633,432270,00030,000
Net income
-21m
L+24.71%
-1,855,299-335,728-471,512-3,407,270-2,964,052-2,508,098-4,189,311-6,202,329-6,500,476-7,584,660-13,069,944-16,480,000-20,553,000
CFO
-20m
L+33.21%
00-715,192-3,209,590-2,764,089-2,130,802-3,967,356-3,975,735-6,265,728-9,819,766-10,313,736-15,213,000-20,265,000

Profile

Alzinova AB (publ), a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease in Sweden. Its lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease; and ALZ-201, a monoclonal antibody that is used for the treatment of toxic Aß oligomers. The company was founded in 2011 and is based in Mölndal, Sweden.
URL
https://www.alzinova.com/
IPO date
Nov 25, 2015
Employees
4
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
30
-88.89%
270
-98.38%
16,633
-3.97%
Cost of revenue
(16,781)
(19,604)
(16,633)
Unusual Expense (Income)
NOPBT
16,811
19,874
33,267
NOPBT Margin
56,036.67%
7,360.74%
200.00%
Operating Taxes
(18)
Tax Rate
NOPAT
16,811
19,874
33,285
Net income
(20,553)
24.71%
(16,480)
26.09%
(13,070)
72.32%
Dividends
Dividend yield
Proceeds from repurchase of equity
40,171
26,284
36,860
BB yield
-13.07%
-21.34%
-54.61%
Debt
Debt current
Long-term debt
800
800
Deferred revenue
Other long-term liabilities
799
(800)
Net debt
(15,496)
(21,226)
(31,238)
Cash flow
Cash from operating activities
(20,265)
(15,213)
(10,314)
CAPEX
(16,781)
(16,633)
Cash from investing activities
(16,781)
(19,604)
(16,633)
Cash from financing activities
30,517
24,805
30,149
FCF
16,811
19,874
33,285
Balance
Cash
15,496
22,026
32,038
Long term investments
Excess cash
15,494
22,012
31,206
Stockholders' equity
(172,192)
(146,596)
(39,112)
Invested Capital
296,814
261,254
145,445
ROIC
6.02%
9.77%
25.11%
ROCE
13.49%
17.33%
31.29%
EV
Common stock shares outstanding
88,814
40,516
24,365
Price
3.46
13.82%
3.04
9.75%
2.77
-56.99%
Market cap
307,297
149.49%
123,169
82.50%
67,490
-40.55%
EV
291,801
101,943
36,253
EBITDA
16,811
19,874
33,267
EV/EBITDA
17.36
5.13
1.09
Interest
236
98
19
Interest/NOPBT
1.40%
0.49%
0.06%